QAI Labs Ltd. is a Delaware corporation headquartered in Sugar Land, Texas, building at the intersection of pharma business development, quantum hardware partnerships, and multi-specific antibody engineering — with collaborators across North America, Europe, and Asia-Pacific.
Former Medarex / Bristol-Myers Squibb. Led antibody engineering on three programs to Phase I/II. At QAI Labs, oversees company operations, the NOVA-3 platform, and US-facing partnerships including the IBM Quantum and Quantinuum integrations. Sets the bar for editorial discipline across the public surface — "designed, not screened" is his line. Reports to the board on platform, pipeline, and partnership KPIs.
Serial entrepreneur and clinical physician with deep multi-specific antibody design experience. Co-founded QAI Labs and leads platform development across the NOVA-3 module library, the design pipeline, and the three internal P1 / P2 / P3 programs. Bridges clinical reality into the design loop — every program in the pipeline is filtered through "would this clear a P2 readout?"
Inventor of the proprietary XFab platform for molecular simulation. Owns the quantum-augmented design layer of NOVA-3 — CVaR-VQE active-space corrections, QAOA assignment optimization, and the hardware-software interface to IBM Quantum and Quantinuum. Sets the honesty bar for what quantum can and cannot do today; refuses to claim "demonstrated quantum advantage" because the literature doesn't support it yet.
Engineering, ML/structural biology, BD-APAC, regulatory affairs, and wet-lab operations. Plus we work with partner labs across North America, Europe, and Asia-Pacific for the wet-lab side of the data flywheel.